NYMOX PHARMACEUTICAL CORPORATION Operating Expense
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Operating Expense of $653.00 thousand for the 3-month period ending 2024-09-30, per its 6-K filed 2025-01-02.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:OperatingExpense · last filed 2025-01-02
- NYMOX PHARMACEUTICAL CORPORATION operating expense for the quarter ending 2024-09-30 was $653.00K, a 35.60% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION operating expense for the quarter ending 2023-09-30 was $1.01M, a 31.39% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION operating expense for the quarter ending 2023-06-30 was $1.10M, a 38.01% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION operating expense for the quarter ending 2023-03-31 was $1.39M, a 72.70% decline year-over-year.
| Period end | Operating Expense 3 month | Operating Expense 6 month | Operating Expense 9 month |
|---|---|---|---|
| 2024-09-30 | $653.00K 6-K · filed 2025-01-02 | $3.50M 6-K · filed 2025-01-02 | |
| 2023-09-30 | $1.01M 6-K · filed 2025-01-02 | $2.11M derived: sum of 2 quarters · filed 2025-01-02 | $3.50M 6-K · filed 2025-01-02 |
| 2023-06-30 | $1.10M 6-K · filed 2023-08-14 | $2.48M 6-K · filed 2023-08-14 | |
| 2023-03-31 | $1.39M 6-K · filed 2023-05-12 | ||
| 2022-09-30 | $1.48M 6-K · filed 2023-11-15 | $3.25M derived: sum of 2 quarters · filed 2023-11-15 | $8.32M 6-K · filed 2023-11-15 |
| 2022-06-30 | $1.77M 6-K · filed 2023-08-14 | $6.85M 6-K · filed 2023-08-14 | |
| 2022-03-31 | $5.07M 6-K · filed 2023-05-12 | ||
| 2021-09-30 | $3.29M 6-K/A · filed 2022-11-16 | $7.27M derived: sum of 2 quarters · filed 2022-11-16 | $9.70M 6-K/A · filed 2022-11-16 |
| 2021-06-30 | $3.98M 6-K · filed 2022-08-15 | $6.41M 6-K · filed 2022-08-15 | |
| 2021-03-31 | $2.43M 6-K · filed 2022-05-13 |